Login / Signup

Role of CD5L and SRD5A2 as Prognostic Biomarkers for Hepatocellular Carcinoma.

Yunxiu LuoXiaopeng HuangJiabin ZhanShuai Zhang
Published in: International journal of general medicine (2021)
CD5L can facilitate individualized, targeted therapy for HCC patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • peritoneal dialysis
  • cancer therapy
  • patient reported outcomes
  • patient reported